Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
Mitsubishi Tanabe Pharma said on March 20 that it has filed an application seeking Japanese approval for an additional OD tablet formulation for its SGLT2 inhibitor Canaglu (canagliflozin).The OD form is easier to take for patients who have difficulties swallowing…
To read the full story
Related Article
- Canaglu OD Tablet Version Approved in Japan
March 19, 2024
BUSINESS
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Merck KGaA to Consolidate Japan Life Science Labs at Haneda Hub
September 1, 2026
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…